Primary staging with 2[18F]-FDG-PET/CT and -PET/MRI and radiotherapy response evaluation with MRI in uterine cervical cancer: an interim analysis of a prospective clinical trial [0.03%]
宫颈癌的初始分期使用2[18F]-FDG-PET/CT和-PET/MRI，以及使用MRI评估放射治疗的疗效：前瞻性临床试验的中期分析结果
Maja Aasa,David Lindquist,Ulrika Ottander et al.
Maja Aasa et al.
Background: In uterine cervical cancer (UCC), tumour staging is performed according to the 2018 International Federation of Gynecology and Obstetrics (FIGO) system, where imaging is incorporated, or the more generic Tumou...
B-CLL with negative 18F-FDG PET/CT and intensive solitary lesion on PSMA PET/CT mimicking prostate cancer bone metastases [0.03%]
18F-FDG PET/CT阴性且PSMA PET/CT表现为单发灶的B细胞慢性淋巴瘤模仿前列腺癌骨转移
Theresa Jung,Daniel Neureiter,Gregor Schweighofer-Zwink et al.
Theresa Jung et al.
Positron emission tomography/computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA)-radioligands is currently suggested by several clinical guidelines for the assessment of prostate cancer (PCa) in various clinical set...
Semi-standardized evaluation of extraprostatic extension and seminal vesicle invasion with [18F]PSMA-1007 PET/CT: a comparison to MRI using histopathology as reference [0.03%]
半标准化的[18F]PSMA-1007 PET/CT前列腺外扩展和精囊侵犯评估与使用病理学为参考标准的MRI比较研究
Erland Hvittfeldt,Fredrik Hedeer,Erik Thimansson et al.
Erland Hvittfeldt et al.
Background: Positron emission tomography/computed tomography (PET/CT) with prostate specific membrane antigen ligands (PSMA) is established for use in primary staging of prostate cancer to screen for metastases. It has al...
Real world experience with [99mTc]Tc-HYNIC-iPSMA SPECT prostate cancer detection: interim results from the global NOBLE registry [0.03%]
全球NOBLE登记处[99mTc]Tc-HYNIC-iPSMA SPECT前列腺癌检测的现实世界经验：中期结果
Pete Tually,Virginia García Quinto,Yehia Omar et al.
Pete Tually et al.
Purpose: [99mTc]Tc-HYNIC-iPSMA is a novel technetium-99m-labelled small molecule inhibitor of the prostate-specific membrane antigen (PSMA) for detecting prostate cancer (PC). The objective of this registry was to collect...
Predictive role of [18F]FDG PET-CT radiomic parameters for KRAS/BRAF/EGFR mutations in metastatic colorectal cancer patients [0.03%]
[18F]FDG PET-CT影像组学参数预测转移性结直肠癌患者KRAS/BRAF/EGFR基因突变的作用
Magdi A Ali,Omar Shebl Zahra,Mohmed I Morsi et al.
Magdi A Ali et al.
Objectives: The objective of this study was to evaluate the predictive value of 18F-fluorodeoxyglucose [18F]FDG positron emission tomography (PET-CT) radiomic parameters in relation to KRAS/BRAF/EGFR mutations in patients...
The Christie score for post-treatment response assessment PET/CT in patients with head and neck squamous cell carcinoma: a safe and simple scoring system [0.03%]
一种安全简便的头颈部鳞癌治疗后疗效评估PET/CT评分系统—— Christie 评分系统的建立及应用研究
N Baguley,C Barker,S Bonington et al.
N Baguley et al.
Background: Radiotherapy with or without concurrent chemotherapy is a standard of care treatment for patients with head and neck squamous cell carcinoma (HNSCC). Upon completion, patients are referred for a post-treatment...
Brown tumors in primary hyperparathyroidism initially interpreted as bone metastases and multiple gigantocelular tumors: case report [0.03%]
原发性甲状旁腺功能亢进所致的棕色瘤初期误诊为骨转移及多发巨细胞肿瘤：病例报告
Vedrana Gladić Nenadić,Marija Punda,Anita Tabain et al.
Vedrana Gladić Nenadić et al.
Brown tumors or osteitis fibrosa cystica are a rare bone metabolism disorder that may mimic cancer metastasis. It represents a late manifestation of prolonged and mostly unrecognized hyperparathyroidism. In this case report we present a 44-...
Inter- and intra-tumoral heterogeneity on [68Ga]Ga-DOTA-TATE/[68Ga]Ga-DOTA-TOC PET/CT predicts response to [177Lu]Lu-DOTA-TATE PRRT in neuroendocrine tumor patients [0.03%]
[68Ga]Ga-DOTA-TATE /[68Ga]Ga-DOTA-TOC PET/CT上的肿瘤内和肿瘤间的异质性可预测神经内分泌肿瘤患者[177Lu]Lu-DOTA-TATE肽受体放射性核素治疗(PRRT)的疗效
Camila Gadens Zamboni,Ayca Dundar,Sanchay Jain et al.
Camila Gadens Zamboni et al.
Background: Indices of tumor heterogeneity on somatostatin receptor PET/CT scans may potentially serve as predictive biomarkers of treatment efficacy in neuroendocrine tumor (NET) patients undergoing [177Lu]Lu-DOTA-TATE P...
[18F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [18F]Fluciclovine [0.03%]
[18F]PSMA-1007和[18F]氟氯酮用于前列腺癌生化复发的比较研究
Cato C Loeff,Willemijn van Gemert,Bastiaan M Privé et al.
Cato C Loeff et al.
Aim: The objective of this study was to compare the detection rates of [18F]PSMA-1007 and [18F]Fluciclovine in early biochemical recurrence (BCR) of prostate cancer, i.e. with low prostate-specific antigen (PSA) levels (0...
Enhancing the diagnostic capacity of [18F]PSMA-1007 PET/MRI in primary prostate cancer staging with artificial intelligence and semi-quantitative DCE: an exploratory study [0.03%]
利用人工智能和半定量DCE增强[18F]PSMA-1007 PET/MRI在前列腺癌分期中诊断能力的探索性研究
Philip Alexander Glemser,Martin Freitag,Balint Kovacs et al.
Philip Alexander Glemser et al.
Background: To investigate the ability of artificial intelligence (AI)-based and semi-quantitative dynamic contrast enhanced (DCE) multiparametric MRI (mpMRI), performed within [18F]-PSMA-1007 PET/MRI, in differentiating ...